5- 1-Hydroxyl-1-methylethyl -2-propyl-imidazol-4-yl carboxylic acid ethyl ester CAS 144689-93-0

Payment Terms: T/T,L/C,WU
skype
Trade on HiSupplier, Worry Free Guarantee
Trading safety, secure your money, lower the risk, protect both buyers and suppliers
HiSupplier is a Chinese multinational company in U.S, it helps to coordination and order landing.
More ›
  • Product Details
  • Company Profile
  • Product Reviews
Basic Info.
  • Brand: MOSINTER 
  • CAS: 144689-93-0 
  • Flash point: 229.723°C 
  • Appearance: White or off-white powder 
  • Melting Point: 98-100°C 
  • Assay: ≥98.0% 
  • Molecular formula: C12H20N2O3 
  • Molecular weight: 240.2988 
  • Boiling point: 456.234°C at 760 mmHg 
  • Refractive index: 1.521 
  • Model No.: MOSINTER 
  • Place of Origin: Zhejiang  
  • Min.Order: 25 Kilogram
  • Means of Transport: Ocean, Air, Land
Supply Capacity
  • Production Capacity: 100Ton/Year
  • Packing:According to the request of customer
  • Delivery Date: Within 7 days

[5-(1-Hydroxyl-1-methylethyl)-2-propyl-imidazol-4-yl]carboxylic acid ethyl ester (CAS: 144689-93-0) is one of Olmesartan intermediates. 


Attribute

Molecular Formula

C12H20N2O3

Molecular Weight

240.2988

Density

1.131g/cm3

Melting point

98-100°C

Boiling point

456.234°C at 760 mmHg

Refractive index

1.521

Flash point

229.723°C

Vapour Pressur

0mmHg at 25°C

Molecular Formula

 

Synonyms: 4-(1-hydroxy-1-methylethyl)-2-propyl-1h-imidazole-5-carboxylic acid ethyl ester; [5-(1-Hydroxyl-1-methylethyl)-2-propyl-imidazol-4-yl] carboxylic acid ethyl ester; 1H-Imidazole-4-carboxylicacid,5-(1-hydroxy-1-methylethyl)-2-propyl-,ethylester; ethyl 5-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-4-carboxylate; 4-(1-Hydroxy-1-methylethyl)-2-propyl-imidazole carboxylic acid ethyl ester; Ethyl-4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-, ethyl ester; Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylate; 1H-Imidazole-4-carboxylic acid,5-(1-hydroxy-1-methylethyl)-2-propyl-,ethyl ester; Ethyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate


Olmesartan medoxomil is an angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form, olmesartan (RNH-6270).

 

Indications

Olmesartan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. The U.S. Food and Drug Administration (FDA) has determined that the benefits of Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label.

 

Contraindications

Contraindications for treatment with olmesartan include biliary obstruction. Another major contraindication is pregnancy; reports in the scientific literature reveal fetal malformations for pregnant women taking sartan-derived medicine.

 

Cautions

Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis. Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist.

 

Adverse effects

The incidence of adverse effects with Benicar (the US trade name for olmesartan medoxomil) is reported as similar to placebo; the only adverse effect that occurred in >1% of patients treated with it and more frequently than placebo was dizziness (3% vs 1%). The full prescribing information for Benicar notes as with all medicine that act directly on the renin-angiotensin system, olmesartan is contraindicated in pregnancy and can cause injury and even death to the developing fetus. In studies of angiotensin II receptor antagonists such as olmesartan, patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.[5] Rarely, olmesartan can cause severe gastrointestinal issues. The symptoms, which include nausea, vomiting, diarrhea, weight loss, and electrolyte abnormalities, are common among those who have celiac disease.

 

Structure

The olmesartan molecule includes one tetrazole group (a five-member heterocyclic ring of four nitrogen atoms and one carbon atom) and one imidazole group (a five-membered planar heterocyclic aromatic ring of two nitrogen and three carbon atoms, classified as an alkaloid).

 

Mechanism of action

Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. It works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.


Appearance: white or off-white crystalline powder

Packing: 25KG drum


Send message to this supplier
Mr. Fedor
Tel: +86-574-89212210
Mobile: +86-18989305995
Enter between 20 to 3,000 chatacters.
Contact Method
MOSINTER GROUP LIMITED
Guangbo Center Office 2001, YinXianDaDao 1357, Ningbo, Zhejiang, China (Mainland) / 315100
Fax: +86-574-89212215
Didn't find what you're looking for? Post Buying Lead or contact our customer service specialist for help!
Buyer Help Center